Dicerna and Kyowa Hakko enter cancer deal
RNAi company Dicerna and Kyowa Hakko Kirin will together develop drug delivery systems and new Dicer Substrate siRNA (DsiRNA) therapies for solid tumors.
- Drug Delivery
- Antisense, Oligonucleotides
- Includes Contract
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.